Drug Trial Radar · NCT03869892
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
856
Actual
Start
Mar 21, 2019
Primary completion
Jun 29, 2021
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Institut de Recherches Internationales ServierAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ADIR, a Servier Group company
- First posted
- Mar 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab.
Conditions
- Metastatic Colorectal Cancer
Interventions
Trifluridine/tipiracil hydrochloride (S95005)Drug
Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.
CapecitabineDrug
Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
Bevacizumab experimentalBiological
Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
Bevacizumab controlBiological
Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Up to 24 months
Locations
190 sites in 25 countries. Site status is shown where the registry gives one.
Centro de Oncología e Investigación de Buenos Aires COIBA
Berazategui, Argentina
Hospital de Gastroenterología Dr. Carlos Borino Udaondo Oncology Unit
Buenos Aires, Argentina
Fundación Favaloro Oncology Unit
Buenos Aires, Argentina
Instituto Alexander Fleming
Buenos Aires, Argentina
Hospital Universitario CEMIC Servicio de Oncología, Unidad de tumores gastrointestinales
Buenos Aires, Argentina
Centro Oncológico Riojano Integral CORI Fundación CORI para la Investigación y Prevención del Cáncer
La Rioja, Argentina
Fundación COIR Centro Oncológico de Interación Regional
Mendoza, Argentina
Centro Médico San Roque
San Miguel de Tucumán, Argentina
Instituto de Oncología de Rosario
Santa Fe, Argentina
ISIS Centro especializado
Santa Fe, Argentina
Blacktown Hospital Cancer and Haematology Centre
Blacktown, Australia
Frankston Private Peninsula and Southeast Oncology Group
Frankston, Australia
Lake Macquarie Private Hospital
Gateshead, Australia
St George Hospital St George Hospital Cancer Care Centre
Kogarah, Australia
Adventist HealthCare Integrated Cancer Centre
Wahroonga, Australia
Southern Medical Day Care Centre
Wollongong, Australia
Med. Universität Graz Klinische Abteilung für Onkologie
Graz, Austria
Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V
Innsbruck, Austria
Ordensklinikum Linz Barmherzige Schwestern Interne I
Linz, Austria
Landeskrankenhaus (SALK) Universitätsklinik für Innere Medizin III (SALK)
Salzburg, Austria
Universitätsklinikum St. Pölten Klinische Abteilung für Innere Medizin I
Sankt Pölten, Austria
Allgemeines Krankenhaus - Universitätskliniken Klinische Abteilung für Onkologie
Vienna, Austria
Hospital do Câncer de Barretos - Fundação Pio XII Unidade de Pesquisa Clínica
Barretos, Brazil
Cenantron - Clinica
Belo Horizonte, Brazil
Sirio Libanes DF - Centro de Oncologia de Braslia do Sirio- Centro Intergrado de Pesquisa
Brasília, Brazil
Centro de Pesquisa Hospital de Caridade de Ijuí Unidade de Pesquisa Clínica
Ijuí, Brazil
Hospital Mae de Deus Oncologia
Porto Alegre, Brazil
Hospital São Rafael Centro Intergrado de Pesquisa
Salvador, Brazil
CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncol Centro Intergrado de Pesquisa
Santo André, Brazil
Hospital de Base Centro Integrado de Pesquisa
São José do Rio Preto, Brazil
ICESP - Instituto do Câncer do Estado de São Paulo Centro Integrado de Pesquisa
São Paulo, Brazil
Hospital A C Camargo Unidade de Pesquisa Clinica
São Paulo, Brazil
"Complex oncology center - Burgas" EOOD Department of medical oncology
Burgas, Bulgaria
"Multiprofile hosp. for active treatmen Dr. Tota Venkova" AD Department of medical oncology
Gabrovo, Bulgaria
"Complex oncology center - Plovdiv" EOOD, IInd base Dpt. of Med. oncology and onc. diseases in gastroenterology
Plovdiv, Bulgaria
"Medical Center Nadezhda Clinical" EOOD Medical Oncology Department
Sofia, Bulgaria
"UMHAT Sv. Ivan Rilski" EAD Clinic of clinical hematology, Dpt. of medical oncology
Sofia, Bulgaria
MHAT Serdika EOOD Department of Medical Oncology
Sofia, Bulgaria
Spec. hospital for active treatment of oncology dis. EOOD Department of medical oncology and palliative care
Sofia, Bulgaria
SHAT of oncology diseases Dr. Marko Antonov Markov" EOOD Department of medical oncology and palliative therapy
Varna, Bulgaria
Showing 40 of 190 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.